Gajanayaka Mudalige N.T., Nadaraja K.

DISRUPTION OF INSULIN STIMULATED GLUT 4 MEMBRANE TRANSLOCATION IN TYPE 2 DIABETES

Tutor: Senior lecturer Pravalinski A.V.
Department of Normal and Pathological Physiology
Gomel State Medical University, Gomel

Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion and insulin resistance. A primary cellular defect underlying insulin resistance is the disruption of insulin-stimulated glucose transporter type 4 (GLUT4) translocation in insulin-sensitive tissues, specifically skeletal muscle and adipose tissue. This review summarizes the mechanisms responsible for impaired GLUT4 trafficking and highlights potential therapeutic targets.

Under physiological conditions, insulin binding to its receptor initiates a signaling cascade involving insulin receptor substrate (IRS) proteins, phosphoinositide 3-kinase (PI3K), and Akt (Protein Kinase B). A critical downstream target of Akt is AS160 (TBC1D4), which acts as a molecular switch for GLUT4 mobilization. In T2DM, reduced tyrosine phosphorylation of IRS proteins and impaired activation of Akt lead to insufficient signaling. This failure to deactivate AS160 prevents GLUT4-containing vesicles from leaving their intracellular storage pools.

Beyond signaling, alterations in the vesicle trafficking machinery itself contribute significantly to insulin resistance. The final step of GLUT4 integration into the plasma membrane requires the assembly of SNARE complexes (including Syntaxin 4 and VAMP2). In T2DM, the efficiency of this "docking and fusion" process is decreased. Furthermore, cytoskeletal remodeling-specifically the formation of cortical actin filaments-is essential for vesicle movement. This process is often impaired due to defective Rac1 signaling, a pathway parallel to Akt that is significantly blunted in diabetic skeletal muscle.

Emerging evidence indicates that endoplasmic reticulum (ER) stress and impaired autophagy contribute to defective GLUT4 translocation. Chronic metabolic stress disrupts normal protein folding and can lead to the mis-sorting of GLUT4 into "static" intracellular compartments or lysosomal degradation, reducing the pool of transporters available for translocation. Additionally, genetic susceptibility and epigenetic modifications can downregulate the expression of key trafficking proteins, further aggravating the defect.

Chronic low-grade inflammation and lipid accumulation are critical drivers of this pathology. Pro-inflammatory cytokines (e.g., TNF-a) activate serine kinases like JNK and IKK B, which inhibit IRS-1 function through inhibitory serine phosphorylation. Simultaneously, increased intracellular lipids (ceramides and diacylglycerols) promote mitochondrial dysfunction and oxidative stress, creating a feedback loop that sustains insulin resistance.

Recent studies suggest that physical activity, pharmacological agents (such as Metformin and TZDs), and novel molecular therapies can partially restore GLUT4 translocation by improving insulin sensitivity and reducing cellular stress. Understanding the precise molecular "roadblocks" in GLUT4 trafficking remains essential for developing targeted interventions to restore glucose homeostasis in T2DM patients.